SAB4700155

Monoclonal Anti-CD33-FITC antibody produced in mouse

clone WM53, purified immunoglobulin, buffered aqueous solution

• UNSPSC Code: 12352203
• NACRES: NA.44

Properties

• biological source: mouse
• conjugate: FITC conjugate
• antibody form: purified immunoglobulin
• antibody product type: primary antibodies
• clone: WM53, monoclonal
• form: buffered aqueous solution
• species reactivity: nonhuman primates, human
• technique(s): flow cytometry: suitable
• isotype: IgG1
• NCBI accession no.: NM_001082618.1
• UniProt accession no.: P20138
• shipped in: wet ice
• storage temp.: 2-8°C
• target post-translational modification: unmodified
• Gene Information: human ... CD33(945)

Description

General description

Myeloid cell surface antigen CD33, (cluster of differentiation 33) also known as SIGLEC3, siglecs (sialic acid binding Ig-like lectins) and GP67, belongs to the CD33-related SIGLEC gene family. It is a type 1 transmembrane protein and contains two immunoglobulin-like extracellular domains, a single transmembrane area and two intracellular inhibitory motifs. The CD33 gene is mapped to human chromosome 19q13.41.

The antibody WM53 reacts with CD33, a 67 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells; it is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.

Immunogen

Human AML cells

Application

The reagent is designed for Flow Cytometry analysis of human blood cells using 4 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial is sufficient for 100 tests.

Biochem/physiol Actions

Association of CD33 (cluster of differentiation 33) with sialic acid-containing ligands causes suppression of proinflammatory pathways in monocytes and macrophages. It is mainly involved in anti-inflammatory signaling, cell adhesion and endocytosis functions. CD33 also works as a myeloid differentiation marker. Mutations in the CD33 gene are associated with Alzheimer′s disease susceptibility and acute myeloid leukemia treatment efficacy. In microglia, increase in the expression of CD33 decreases amyloid β peptide phagocytosis.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Solution in phosphate buffered saline containing 15 mM sodium azide and 0.2% high-grade protease free BSA as a stabilizing agent.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable